182 related articles for article (PubMed ID: 11083647)
61. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant.
Lai MW; Yeh CT
Antivir Ther; 2008; 13(7):875-9. PubMed ID: 19043921
[TBL] [Abstract][Full Text] [Related]
62. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.
Ji D; Liu Y; Li L; Xu Z; Si LL; Dai JZ; Li X; Wang L; Yao Z; Xin SJ; Chen GF; Xu D
J Clin Virol; 2012 May; 54(1):66-72. PubMed ID: 22398037
[TBL] [Abstract][Full Text] [Related]
63. Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA.
Morrissey DV; Lee PA; Johnson DA; Overly SL; McSwiggen JA; Beigelman L; Mokler VR; Maloney L; Vargeese C; Bowman K; O'Brien JT; Shaffer CS; Conrad A; Schmid P; Morrey JD; Macejak DG; Pavco PA; Blatt LM
J Viral Hepat; 2002 Nov; 9(6):411-8. PubMed ID: 12431202
[TBL] [Abstract][Full Text] [Related]
64. Inhibition of hepatitis B virus replication by quercetin in human hepatoma cell lines.
Cheng Z; Sun G; Guo W; Huang Y; Sun W; Zhao F; Hu K
Virol Sin; 2015 Aug; 30(4):261-8. PubMed ID: 26268473
[TBL] [Abstract][Full Text] [Related]
65. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.
Yatsuji H; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Iwao E; Fujimoto Y; Ochi H; Abe H; Maekawa T; Tateno C; Yoshizato K; Suzuki F; Kumada H; Chayama K
Antimicrob Agents Chemother; 2006 Nov; 50(11):3867-74. PubMed ID: 16982790
[TBL] [Abstract][Full Text] [Related]
66. Profound suppression of hepatitis B virus replication with lamivudine.
Lai CL; Yuen MF
J Med Virol; 2000 Jul; 61(3):367-73. PubMed ID: 10861648
[TBL] [Abstract][Full Text] [Related]
67. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro.
Colledge D; Locarnini S; Shaw T
Hepatology; 1997 Jul; 26(1):216-25. PubMed ID: 9214473
[TBL] [Abstract][Full Text] [Related]
68. Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs.
Huang H; Zhou W; Zhu H; Zhou P; Shi X
Toxicol Appl Pharmacol; 2017 May; 323():36-43. PubMed ID: 28322895
[TBL] [Abstract][Full Text] [Related]
69. Reverse transcriptase activity of hepatitis B virus (HBV) DNA polymerase within core capsid: interaction with deoxynucleoside triphosphates and anti-HBV L-deoxynucleoside analog triphosphates.
Lam W; Li Y; Liou JY; Dutschman GE; Cheng YC
Mol Pharmacol; 2004 Feb; 65(2):400-6. PubMed ID: 14742682
[TBL] [Abstract][Full Text] [Related]
70. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
71. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.
König A; Yang J; Jo E; Park KHP; Kim H; Than TT; Song X; Qi X; Dai X; Park S; Shum D; Ryu WS; Kim JH; Yoon SK; Park JY; Ahn SH; Han KH; Gerlich WH; Windisch MP
J Hepatol; 2019 Aug; 71(2):289-300. PubMed ID: 31077792
[TBL] [Abstract][Full Text] [Related]
72. Hepatitis B virus resistance to lamivudine and its clinical implications.
Liu X; Schinazi RF
Antivir Chem Chemother; 2002 May; 13(3):143-55. PubMed ID: 12448687
[TBL] [Abstract][Full Text] [Related]
73. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Zhu Y; Curtis M; Borroto-Esoda K
Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
[TBL] [Abstract][Full Text] [Related]
74. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C
Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247
[TBL] [Abstract][Full Text] [Related]
75. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.
Bartholomew MM; Jansen RW; Jeffers LJ; Reddy KR; Johnson LC; Bunzendahl H; Condreay LD; Tzakis AG; Schiff ER; Brown NA
Lancet; 1997 Jan; 349(9044):20-2. PubMed ID: 8988118
[TBL] [Abstract][Full Text] [Related]
76. In vitro evaluation of combination therapies against hepatitis B virus replication.
Korba BE
Antiviral Res; 1996 Jan; 29(1):49-51. PubMed ID: 8721544
[TBL] [Abstract][Full Text] [Related]
77. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.
Lok AS; Zoulim F; Locarnini S; Mangia A; Niro G; Decraemer H; Maertens G; Hulstaert F; De Vreese K; Sablon E
J Clin Microbiol; 2002 Oct; 40(10):3729-34. PubMed ID: 12354872
[TBL] [Abstract][Full Text] [Related]
78. Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV.
Semaine W; Johar M; Tyrrell DL; Kumar R; Agrawal B
J Med Chem; 2006 Mar; 49(6):2049-54. PubMed ID: 16539393
[TBL] [Abstract][Full Text] [Related]
79. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.
Yang H; Westland CE; Delaney WE; Heathcote EJ; Ho V; Fry J; Brosgart C; Gibbs CS; Miller MD; Xiong S
Hepatology; 2002 Aug; 36(2):464-73. PubMed ID: 12143057
[TBL] [Abstract][Full Text] [Related]
80. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations.
Wang XY; Wei ZM; Wu GY; Wang JH; Zhang YJ; Li J; Zhang HH; Xie XW; Wang X; Wang ZH; Wei L; Wang Y; Chen HS
Antivir Ther; 2012; 17(5):793-803. PubMed ID: 22668794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
